Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. - Concepedia

Concepedia

Publication | Closed Access

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

152

Citations

7

References

1995

Year

David Rinaldi, Howard A. Burris, F. Andrew Dorr, James R. Woodworth, John G. Kuhn, John R. Eckardt, Gladys Rodriguez, Silvia Corso, Suzanne M. Fields, Chris Langley

Journal of Clinical Oncology

Abstract

The dose-limiting toxicity, MTD, and recommended phase II dose of LY231514 when administered weekly for 4 weeks every 42 days are neutropenia, 40 mg/m2, and 30 mg/m2, respectively.

References

	Year	Citations

Page 1